Suppr超能文献

Gene-panel sequencing and the prediction of breast-cancer risk.

作者信息

Easton Douglas F, Pharoah Paul D P, Antoniou Antonis C, Tischkowitz Marc, Tavtigian Sean V, Nathanson Katherine L, Devilee Peter, Meindl Alfons, Couch Fergus J, Southey Melissa, Goldgar David E, Evans D Gareth R, Chenevix-Trench Georgia, Rahman Nazneen, Robson Mark, Domchek Susan M, Foulkes William D

机构信息

From the Departments of Public Health and Primary Care (D.F.E., P.D.P.P., A.C.A.), Oncology (D.F.E., P.D.P.P.), and Medical Genetics (M.T.), University of Cambridge, Cambridge, the Centre for Genomic Medicine, Institute of Human Development, Manchester Academic Health Science Centre, University of Manchester and St. Mary's Hospital, Manchester (D.G.R.E.), and the Division of Genetics and Epidemiology, Institute of Cancer Research, London (N.R.) - all in the United Kingdom; the Departments of Oncological Sciences (S.V.T.) and Dermatology (D.E.G.), Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City; the Basser Research Center for BRCA and Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (K.L.N., S.M.D.); the Department of Human Genetics and Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands (P.D.); the Department of Obstetrics and Gynecology, Division of Tumor Genetics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany (A.M.); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN (F.J.C.); the Department of Pathology, School of Biomedical Sciences, Faculty of Medicine, Dentistry, and Health Sciences at the University of Melbourne, Parkville, VIC (M.S.), and the QIMR Berghofer Medical Research Institute, Herston, QLD (G.C.-T.) - both in Australia; the Clinical Genetics Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (M.R.); and the Program in Cancer Genetics, Departments of Human Genetics and Oncology, the Lady Davis Institute for Medical Research, and the Research Institute of the McGill University Health Center, McGill University, Montreal (W.D.F.).

出版信息

N Engl J Med. 2015 Jun 4;372(23):2243-57. doi: 10.1056/NEJMsr1501341. Epub 2015 May 27.

Abstract
摘要

相似文献

1
Gene-panel sequencing and the prediction of breast-cancer risk.
N Engl J Med. 2015 Jun 4;372(23):2243-57. doi: 10.1056/NEJMsr1501341. Epub 2015 May 27.
2
3
US panel rejects routine use of BRCA cancer screening in women.
BMJ. 2013 Apr 4;346:f2160. doi: 10.1136/bmj.f2160.
4
Curating the way to better determinants of genetic risk.
N Engl J Med. 2015 Jun 4;372(23):2227-8. doi: 10.1056/NEJMe1506276. Epub 2015 May 27.
5
Unclassified variants in BRCA genes: guidelines for interpretation.
Ann Oncol. 2011 Jan;22 Suppl 1:i18-23. doi: 10.1093/annonc/mdq661.
6
Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
J Med Genet. 2005 Mar;42(3):e20. doi: 10.1136/jmg.2004.027243.
7
USPSTF recommends BRCA testing in women based on familial history.
Am J Manag Care. 2014 Mar;20(5 Spec No.):E6.
8
ClinGen and Genetic Testing.
N Engl J Med. 2015 Oct;373(14):1377. doi: 10.1056/NEJMc1508700.
9
ClinGen and Genetic Testing.
N Engl J Med. 2015 Oct;373(14):1377. doi: 10.1056/NEJMc1508700.
10
ClinGen and Genetic Testing.
N Engl J Med. 2015 Oct;373(14):1377-8. doi: 10.1056/NEJMc1508700.

引用本文的文献

2
The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers.
Biomark Res. 2025 Aug 20;13(1):108. doi: 10.1186/s40364-025-00814-x.
3
Carcinogenic form and characteristics of BRCA pathogenic variant breast cancer.
Int J Clin Oncol. 2025 Aug 17. doi: 10.1007/s10147-025-02853-8.
7
Impact of germline variants on breast and ovarian cancer risk in Japanese women: an original cohort study and meta-analysis.
EBioMedicine. 2025 Jun;116:105758. doi: 10.1016/j.ebiom.2025.105758. Epub 2025 May 21.
10
Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2, and PALB2.
Cancer Res Commun. 2025 May 1;5(5):783-791. doi: 10.1158/2767-9764.CRC-24-0592.

本文引用的文献

1
The FDA and genomic tests--getting regulation right.
N Engl J Med. 2015 Jun 4;372(23):2258-64. doi: 10.1056/NEJMsr1501194. Epub 2015 May 27.
2
Mutations in RECQL Gene Are Associated with Predisposition to Breast Cancer.
PLoS Genet. 2015 May 6;11(5):e1005228. doi: 10.1371/journal.pgen.1005228. eCollection 2015 May.
3
Germline RECQL mutations are associated with breast cancer susceptibility.
Nat Genet. 2015 Jun;47(6):643-6. doi: 10.1038/ng.3284. Epub 2015 Apr 27.
4
Age-specific risk of breast cancer in women with neurofibromatosis type 1.
Br J Cancer. 2015 Apr 28;112(9):1546-8. doi: 10.1038/bjc.2015.78. Epub 2015 Mar 5.
5
Cutting the Gordian helix--regulating genomic testing in the era of precision medicine.
N Engl J Med. 2015 Mar 26;372(13):1185-6. doi: 10.1056/NEJMp1501964. Epub 2015 Feb 17.
7
Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15172-7. doi: 10.1073/pnas.1407909111. Epub 2014 Oct 6.
9
Breast-cancer predisposition in multiple endocrine neoplasia type 1.
N Engl J Med. 2014 Aug 7;371(6):583-4. doi: 10.1056/NEJMc1406028.
10
Breast-cancer risk in families with mutations in PALB2.
N Engl J Med. 2014 Aug 7;371(6):497-506. doi: 10.1056/NEJMoa1400382.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验